Please use this identifier to cite or link to this item:
http://ri.uaemex.mx/handle20.500.11799/113193| DC Field | Value | Language |
|---|---|---|
| dc.creator | BRANDON ITURBE ESQUIVEL | - |
| dc.creator | José Meneses Calderón | - |
| dc.creator | Luis Edgar Concepción Carrillo | - |
| dc.creator | Hugo Mendieta Zerón | - |
| dc.date | 2022-05-30 | - |
| dc.date.accessioned | 2022-08-05T06:02:20Z | - |
| dc.date.available | 2022-08-05T06:02:20Z | - |
| dc.identifier | http://hdl.handle.net/20.500.11799/113193 | - |
| dc.identifier.uri | http://ri.uaemex.mx/handle20.500.11799/113193 | - |
| dc.description | Combined treatments against SARS-CoV-2 are emerging and some have taken into account the post-COVID-19 fibrosis. The aim of this survey was to report the experience of treating COVID-19 patients with pirfenidone, nitazoxanide (NTZ) and colchicine. It was a case series report of COVID-19 patients treated from December 2020 to March 2021, in a rural health center located in the State of Mexico, Mexico. 23 patients were included (mean age 44.5 ± 17.1 years), 12 women (mean age 45.9 ± 17.9 years) and 11 men (mean age 43 ± 16.9 years) with four deaths (17.39%). The evolution time was of 17.3 ± 6.7 days being the main symptoms fever (82.6%), myalgia (69.6%) and cough (65.2%). The main comorbidities were overweight/obesity 18 (78.26%), type 2 diabetes mellitus (T2DM) 4 (17.39%), Chronic obstructive pulmonary disease (COPD) 5 (21.73%) and systemic hypertension 2 (8.69%). Two patients were intubated and both died; in these cases, they refused to take NTZ until after three days the medical doctor had prescribed it for the first time. It can be concluded that implementing a mixed treatment with pirfenidone, NTZ and colchicine could improve the survival rate in ambulatory patients of low socioeconomic status. | - |
| dc.language | eng | - |
| dc.publisher | PAGEPress srl, Italy | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | - |
| dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0 | - |
| dc.source | 1122-0643 | - |
| dc.subject | COVID-19 | - |
| dc.subject | Pirfenidone | - |
| dc.subject | Nitazoxanide | - |
| dc.subject | Colchicine | - |
| dc.subject | info:eu-repo/classification/cti/3 | - |
| dc.title | Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series | - |
| dc.type | article | - |
| dc.audience | students | - |
| dc.audience | researchers | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| Appears in Collections: | Producción | |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.